Biotechnology Acquisitions in 2018

Thompson Street Capital Partners (TSCP), a St. Louis-based private equity firm, has partnered with management to acquire Seattle-based LifeSpan Biosciences, Inc. (LSBio), a developer and e‑commerce distributor of antibodies, kits, proteins and related reagents for academic and pharmaceutical research. TSCP said it will support LSBio's strategy to expand its catalog and capabilities organically and via targeted acquisitions; terms were not disclosed.

Keensight Capital has acquired a majority stake in Biovian, a Finnish contract development and manufacturing organization (CDMO) for biopharmaceuticals, alongside the company's founders, managers and Edmond de Rothschild Equity Strategies (ERES) funds. Biovian, founded in 2003 and based in Finland with ~70 employees, provides end-to-end GMP manufacturing, development and analytical services for biologics, gene therapies and vaccines; Keensight will support scaling the business to become a leading European biologics CDMO.